Developed at KU Leuven, the GIPXplorePLUZ solution combines capture-based targeted sequencing with a fragmentomics approach, representing a major step beyond conventional liquid biopsy methods. This tumour-naïve molecular profiling offers a new alternative for early cancer detection and minimal residual disease (MRD) monitoring. The offering includes the necessary reagents, dedicated Bio-IT pipelines developed by KU Leuven, and OncoDNA’s advanced OncoKDM® platform which will be used for the interpretation support.